{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:39:27Z","timestamp":1793907567053,"version":"4.8.0"},"reference-count":618,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.metabol.2022.155332","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T03:34:30Z","timestamp":1665545670000},"page":"155332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":153,"special_numbering":"C","title":["Pharmacotherapy of type 2 diabetes: An update and future directions"],"prefix":"10.1016","volume":"137","author":[{"given":"Antea","family":"DeMarsilis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyoti","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Boutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Filippaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Sternthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2022.155332_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0015","article-title":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants (vol 387, pg 1513, 2016)","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.diabres.2007.05.004","article-title":"Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies","volume":"78","author":"Gerstein","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1900\/RDS.2012.9.6","article-title":"Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications","volume":"9","author":"Murea","year":"2012","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.metabol.2022.155332_bb0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0040","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2011.04.008","article-title":"Effects of leptin and adiponectin on pancreatic \u03b2-cell function","volume":"60","author":"Lee","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0045","first-page":"193","article-title":"Insulin resistance: the clinical spectrum","volume":"6","author":"Mantzoros","year":"1995","journal-title":"Adv Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154890","article-title":"Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies","volume":"124","author":"Ricciardi","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality","volume":"314","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb0060","doi-asserted-by":"crossref","first-page":"1905194","DOI":"10.1155\/2019\/1905194","article-title":"Diabetes mellitus and its cardiovascular complications: new insights into an old disease","volume":"2019","author":"Sardu","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154712","article-title":"Role of the gut microbiota in type 2 diabetes and related diseases","volume":"117","author":"Yang","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154910","article-title":"Heart failure in diabetes","volume":"125","author":"Jankauskas","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0075","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.3390\/jcm10163682","article-title":"Diabetes mellitus and heart failure","volume":"10","author":"Triposkiadis","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154838","article-title":"Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes","volume":"123","author":"Yun","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154892","article-title":"Insulin resistance and insulin sensitizing agents","volume":"125","author":"Mastrototaro","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2047487319881021","article-title":"The global epidemics of diabetes in the 21st century: current situation and perspectives","volume":"26","author":"Standl","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb0095","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1210\/jc.2004-0087","article-title":"Insulin resistance and vascular dysfunction in nondiabetic Asian Indians","volume":"89","author":"Raji","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108025","article-title":"Metformin: an old drug against old age and associated morbidities","volume":"160","author":"Salvatore","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0110","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/diacare.24.3.489","article-title":"Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects","volume":"24","author":"Mannucci","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0120","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.bbadis.2016.09.019","article-title":"Metformin, beyond an insulin sensitizer, targeting heart and pancreatic \u03b2 cells","volume":"1863","author":"Yang","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.metabol.2022.155332_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2337\/dc15-0488","article-title":"The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies","volume":"39","author":"Buse","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0130","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1530\/EJE-07-0500","article-title":"Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes","volume":"158","author":"Lund","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2337\/diacare.14.4.342","article-title":"Double-blind evaluation of efficacy and tolerability of metformin in NIDDM","volume":"14","author":"Dornan","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2022.155332_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.diabet.2019.10.006","article-title":"Challenging 2019 ESC guidelines for the management of type 2 diabetes","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0160","first-page":"S125","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0165","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.metabol.2022.155332_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155160","article-title":"Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure","volume":"130","author":"Schernthaner","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0175","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0185","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0190","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s40261-017-0564-6","article-title":"Lactate levels with chronic metformin use: a narrative review","volume":"37","author":"Huang","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.metabol.2022.155332_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11892-017-0829-8","article-title":"Metformin: new preparations and nonglycemic benefits","volume":"17","author":"Fujita","year":"2017","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.metabol.2022.155332_bb0200","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the gastrointestinal tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0205","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jcjd.2018.04.004","article-title":"Safe use of metformin in adults with type 2 diabetes and chronic kidney disease: lower dosages and sick-day education are essential","volume":"43","author":"MacCallum","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0215","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0220","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb0225","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.116.025483","article-title":"Effect of long-term metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium","volume":"136","author":"Goldberg","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb0230","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular outcomes in trials of oral diabetes medications: a systematic review","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0235","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0240","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.biopha.2017.12.023","article-title":"Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control","volume":"98","author":"Sambe","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb0250","doi-asserted-by":"crossref","first-page":"E2869","DOI":"10.3390\/ijms19102869","article-title":"Metabolic effects of metformin in the failing heart","volume":"19","author":"Dziubak","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3173","article-title":"Mechanisms of action of metformin with special reference to cardiovascular protection","volume":"35","author":"Zilov","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0260","series-title":"CSP #2002 - investigation of metformin in pre-diabetes on atherosclerotic cardiovascular OuTcomes (VA-IMPACT)","year":"2021"},{"key":"10.1016\/j.metabol.2022.155332_bb0265","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management","volume":"10","author":"Hendricks","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2022.155332_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.ijo.0803695","article-title":"Metformin and body weight","volume":"32","author":"Golay","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.metabol.2022.155332_bb0275","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4578","article-title":"Effect of metformin monotherapy on serum lipid profile in statin-na\u00efve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study","volume":"6","author":"Lin","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.metabol.2022.155332_bb0280","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2165\/00003495-200363180-00001","article-title":"Metformin: new understandings, new uses","volume":"63","author":"Hundal","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb0285","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.ATV.0000201938.78044.75","article-title":"Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells","volume":"26","author":"Isoda","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2022.155332_bb0290","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/HJH.0000000000001119","article-title":"Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials","volume":"35","author":"Zhou","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2022.155332_bb0295","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.phrs.2016.10.006","article-title":"Metformin: an anti-diabetic drug to fight cancer","volume":"113","author":"Daugan","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117717","article-title":"Anticancer mechanisms of metformin: a review of the current evidence","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0305","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.3390\/cancers11020209","article-title":"Metformin treatment suppresses melanoma cell growth and motility through modulation of microRNA expression","volume":"11","author":"Tseng","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.metabol.2022.155332_bb0310","doi-asserted-by":"crossref","first-page":"836","DOI":"10.12659\/MSM.912059","article-title":"Metformin inhibit lung cancer cell growth and invasion in vitro as well as tumor formation in vivo partially by activating PP2A","volume":"25","author":"Zhou","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.metabol.2022.155332_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172541","article-title":"Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1","volume":"859","author":"Xue","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb0320","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.7314\/APJCP.2014.15.23.10067","article-title":"Antiproliferative effect of metformin on the endometrium - a clinical trial","volume":"15","author":"Tabrizi","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.metabol.2022.155332_bb0325","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1078-0432.CCR-15-1722","article-title":"(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial","volume":"22","author":"Reni","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0330","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3332\/ecancer.2015.563","article-title":"Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas","volume":"9","author":"Braghiroli","year":"2015","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.metabol.2022.155332_bb0335","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1634\/theoncologist.2016-0153","article-title":"Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance)","volume":"21","author":"Singh","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.metabol.2022.155332_bb0340","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s10637-017-0511-7","article-title":"Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial","volume":"35","author":"Parikh","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb0345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-018-05070-2","article-title":"Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial","volume":"174","author":"Nanni","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.metabol.2022.155332_bb0350","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0355","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0360","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/aging.100273","article-title":"If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice","volume":"3","author":"Anisimov","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.metabol.2022.155332_bb0365","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025932","article-title":"Metformin: a hopeful promise in aging research","volume":"6","author":"Novelle","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0370","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0375","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a tool to target aging","volume":"23","author":"Barzilai","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0380","series-title":"Endotext","article-title":"Management of type 2 diabetes: selecting amongst available pharmacological agents","author":"Cavaiola","year":"2000"},{"key":"10.1016\/j.metabol.2022.155332_bb0390","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.therap.2021.09.003","article-title":"The discovery of hypoglycaemic sulphonamides - Montpellier, 1942","volume":"76","author":"Lavabre-Bertrand","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.metabol.2022.155332_bb0395","article-title":"History of current non-insulin medications for diabetes mellitus","volume":"2","author":"Quianzon","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.metabol.2022.155332_bb0400","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1126\/science.270.5239.1166","article-title":"Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor","volume":"270","author":"Inagaki","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.metabol.2022.155332_bb0405","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2337\/diabetes.47.9.1412","article-title":"Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels","volume":"47","author":"Gribble","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0410","series-title":"Sulfonylureas and meglitinides: insights into physiology and translational clinical utility","author":"Lebovitz","year":"2015"},{"key":"10.1016\/j.metabol.2022.155332_bb0415","series-title":"StatPearls","article-title":"Sulfonylureas","author":"Costello","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb0420","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0425","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00003495-200565030-00005","article-title":"Oral antidiabetic agents","volume":"65","author":"Krentz","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb0430","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00744.x","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin","volume":"9","author":"Hermansen","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0435","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/dom.12610","article-title":"Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas","volume":"18","author":"Deacon","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0440","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/dom.12287","article-title":"A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0445","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0450","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc06-1789","article-title":"A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin","volume":"30","author":"Gangji","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0455","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/dmrr.235","article-title":"Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide","volume":"17","author":"Holstein","year":"2001","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0460","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/dmrr.2470","article-title":"The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis","volume":"30","author":"Schopman","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0465","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2337\/dc13-0600","article-title":"Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias","volume":"37","author":"Stahn","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0470","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0475","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00125-013-2856-6","article-title":"Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis","volume":"56","author":"Hirst","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0480","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMp068294","article-title":"Finding new treatments for diabetes \u2014 how many, how fast\u2026 how good?","volume":"356","author":"Nathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0485","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1742-1241.2010.02353.x","article-title":"Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study","volume":"64","author":"Seck","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0490","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1307","article-title":"A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses","volume":"105","author":"Maloney","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0495","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1089\/dia.2012.0144","article-title":"The duration of sulfonylurea treatment is associated with \u03b2-cell dysfunction in patients with type 2 diabetes mellitus","volume":"14","author":"Shin","year":"2012","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl","key":"10.1016\/j.metabol.2022.155332_bb0505","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.II. Mortality results","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0510","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13300-020-00812-2","article-title":"Latest evidence on sulfonylureas: what's new?","volume":"11","author":"Leiter","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0515","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/dom.12456","article-title":"Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer","volume":"17","author":"Abdelmoneim","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0520","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0525","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0530","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2337\/dci19-0034","article-title":"A verdict for glimepiride: effective and not guilty of cardiovascular harm","volume":"42","author":"Riddle","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0535","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb0540","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb0545","first-page":"11","article-title":"Pharmacological and pharmaceutical profile of gliclazide: a review","volume":"9","author":"Sarkar","year":"2011","journal-title":"J Appl Pharm Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0550","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2125.1999.00092.x","article-title":"The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes","volume":"48","author":"King","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243783","article-title":"Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis","volume":"15","author":"Yen","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.metabol.2022.155332_bb0565","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1586\/17512433.2016.1159512","article-title":"Is gliclazide a sulfonylurea with difference? A review in 2016","volume":"9","author":"Singh","year":"2016","journal-title":"Exp Rev Clin Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb0570","first-page":"1081","article-title":"Acylaminoalkyl substituted benzoic and phenylalkane acids with hypoglycaemic properties (author's transl)","volume":"28","author":"Geisen","year":"1978","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.metabol.2022.155332_bb0575","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0140-6736(01)06715-0","article-title":"Insulinotropic meglitinide analogues","volume":"358","author":"Dornhorst","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb0585","article-title":"Meglitinide analogues for type 2 diabetes mellitus","volume":"2007","author":"Black","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0590","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1345\/aph.1P136","article-title":"Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus","volume":"44","author":"Phillippe","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb0595","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2165\/00002512-200017050-00007","article-title":"Meglitinide analogues in the treatment of type 2 diabetes mellitus","volume":"17","author":"Landgraf","year":"2000","journal-title":"Drugs Aging"},{"key":"10.1016\/j.metabol.2022.155332_bb0600","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5114\/aoms.2013.34991","article-title":"The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus","volume":"9","author":"Guardado-Mendoza","year":"2013","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0605","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/BF00402171","article-title":"Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells","volume":"38","author":"Gromada","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0610","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1210\/jcem.85.3.6446","article-title":"Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus","volume":"85","author":"Keilson","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.metabol.2022.155332_bb0615","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2362.1999.00005.x","article-title":"Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes","volume":"29","author":"Owens","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155332_bb0620","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/11207600-000000000-00000","article-title":"Repaglinide: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Scott","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb0625","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1530\/EJE-09-0547","article-title":"Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation","volume":"161","author":"McKillop","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0630","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-200241070-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of repaglinide","volume":"41","author":"Hatorp","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2022.155332_bb0635","first-page":"415","article-title":"Pharmacokinetics and metabolism of nateglinide in humans","volume":"29","author":"Weaver","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.metabol.2022.155332_bb0640","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70257-4","article-title":"Meglitinide analogues: a review of clinical data focused on recent trials","volume":"32","author":"Blickl\u00e9","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0645","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2337\/diacare.21.11.1897","article-title":"A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes","volume":"21","author":"Goldberg","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0650","doi-asserted-by":"crossref","first-page":"886","DOI":"10.2337\/diacare.26.3.886","article-title":"Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function","volume":"26","author":"Hasslacher","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0655","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2147\/DMSO.S6621","article-title":"Repaglinide\/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update","volume":"3","author":"Moses","year":"2010","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2022.155332_bb0660","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1067\/mcp.2000.103973","article-title":"Pharmacokinetics of repaglinide in subjects with renal impairment","volume":"67","author":"Marbury","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0665","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/diacare.24.1.11","article-title":"Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes","volume":"24","author":"Moses","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0670","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5414\/CNP60090","article-title":"Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure","volume":"60","author":"Inoue","year":"2003","journal-title":"CN"},{"key":"10.1016\/j.metabol.2022.155332_bb0675","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/clpt.2014.141","article-title":"Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions","volume":"96","author":"Tornio","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0680","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/pr.115.011411","article-title":"Role of cytochrome P450 2C8 in drug metabolism and interactions","volume":"68","author":"Backman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0685","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40264-019-00901-7","article-title":"Hypoglycemia associated with antibiotics alone and in combination with sulfonylureas and meglitinides: an epidemiologic surveillance study of the FDA Adverse Event Reporting System (FAERS)","volume":"43","author":"Kennedy","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.metabol.2022.155332_bb0690","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1046\/j.1463-1326.2000.0022s.x","article-title":"Repaglinide: prandial glucose regulation in clinical practice","volume":"2","author":"Owens","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0695","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8227(01)00253-4","article-title":"Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes","volume":"53","author":"Van Gaal","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0700","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1517\/14656566.1.7.1455","article-title":"A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes","volume":"1","author":"Moses","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb0705","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1574886315666201026125848","article-title":"Efficacy and cardiovascular safety of meglitinides","volume":"16","author":"Philip","year":"2021","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.metabol.2022.155332_bb0710","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2337\/diacare.27.6.1265","article-title":"Repaglinide versus nateglinide monotherapy: a randomized, multicenter study","volume":"27","author":"Rosenstock","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0715","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/archinte.163.11.1306","article-title":"Clinical significance, pathogenesis, and management of postprandial hyperglycemia","volume":"163","author":"Gerich","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0720","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.amjms.2020.01.011","article-title":"Acarbose versus repaglinide in diabetes treatment: a new appraisal of two old rivals","volume":"359","author":"Pishdad","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0725","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-8-23","article-title":"Postprandial hyperglycemia as an etiological factor in vascular failure","volume":"8","author":"Node","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb0730","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.2337\/diabetes.53.suppl_3.S156","article-title":"The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium","volume":"53","author":"Quast","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0735","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8227(03)00057-3","article-title":"Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin","volume":"60","author":"Derosa","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0740","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0750","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.28.1.154","article-title":"Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis","volume":"28","author":"van de Laar","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0755","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1586\/17446651.2014.931807","article-title":"Incretin enhancement without hyperinsulinemia: \u03b1-glucosidase inhibitors","volume":"9","author":"Kalra","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0760","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5114\/aoms.2012.31621","article-title":"\u03b1-Glucosidase inhibitors and their use in clinical practice","volume":"8","author":"Derosa","year":"2012","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb0765","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1517\/14656566.2015.1070827","article-title":"Therapeutic potential of \u03b1-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb0770","article-title":"Review: \u03b1 glucosidase inhibitors improve glycaemic control but have uncertain effects on patient-important outcomes in type 2 diabetes","volume":"10","author":"Isley","year":"2005","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0775","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(13)70021-4","article-title":"Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial","volume":"2","author":"Yang","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0780","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.clinthera.2013.03.020","article-title":"Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis","volume":"35","author":"Zhu","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0785","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.clinthera.2015.05.504","article-title":"Acarbose monotherapy and type 2 diabetes prevention in Eastern and Western prediabetes: an ethnicity-specific meta-analysis","volume":"37","author":"Hu","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb0790","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12933-019-0933-y","article-title":"Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes","volume":"18","author":"Coleman","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb0795","article-title":"Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus","volume":"12","author":"Moelands","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb0800","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose ToleranceThe STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb0805","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb0810","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-021-00690-0","article-title":"Long-term outcomes of adding alpha-glucosidase inhibitors in insulin-treated patients with type 2 diabetes","volume":"21","author":"Yen","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.metabol.2022.155332_bb0815","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jdi.12711","article-title":"Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations","volume":"9","author":"Gao","year":"2018","journal-title":"J Diabetes Investig"},{"issue":"Suppl 3","key":"10.1016\/j.metabol.2022.155332_bb0820","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2337\/diacare.13.3.32","article-title":"Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas","volume":"13","author":"Reaven","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0830","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0835","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","article-title":"Fibrates, glitazones, and peroxisome proliferator-activated receptors","volume":"30","author":"Lalloyer","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2022.155332_bb0840","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0845","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J Adv Pharm Technol Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0850","series-title":"StatPearls","article-title":"Thiazolidinediones","author":"Eggleton","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb0855","series-title":"Endotext","article-title":"Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes","author":"Feingold","year":"2000"},{"key":"10.1016\/j.metabol.2022.155332_bb0860","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/pds.1804","article-title":"Case series of liver failure associated with rosiglitazone and pioglitazone","volume":"18","author":"Floyd","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.metabol.2022.155332_bb0865","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41598-017-01965-0","article-title":"Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2022.155332_bb0870","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042784","volume":"10","author":"Angwin","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.metabol.2022.155332_bb0875","series-title":"TriMaster study shows precision medicine in diabetes is possible","year":"2021"},{"key":"10.1016\/j.metabol.2022.155332_bb0880","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2942","article-title":"Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study","volume":"339","author":"Juurlink","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb0885","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb0890","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb0895","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00252649","article-title":"The effect of insulin on renal sodium metabolism.A review with clinical implications","volume":"21","author":"DeFronzo","year":"1981","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0900","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb0905","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.164.19.2097","article-title":"A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors","volume":"164","author":"Chiquette","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb0910","doi-asserted-by":"crossref","first-page":"E930","DOI":"10.1152\/ajpendo.00522.2004","article-title":"Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue","volume":"288","author":"Rasouli","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0915","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.metabol.2004.07.008","article-title":"Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial","volume":"54","author":"Smith","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0920","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-014-3451-1","article-title":"GLUT2, glucose sensing and glucose homeostasis","volume":"58","author":"Thorens","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb0925","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.2337\/db13-0265","article-title":"Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates","volume":"62","author":"DeFronzo","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb0930","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.metabol.2022.155332_bb0935","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155332_bb0940","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155332_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154844","article-title":"Intestine-liver crosstalk in type 2 diabetes and non-alcoholic fatty liver disease","volume":"123","author":"Nawrot","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0950","article-title":"Metabolic liver disease in diabetes - from mechanisms to clinical trials","volume":"111S","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154868","article-title":"Diabetes and metabolic dysfunction-associated fatty liver disease","volume":"123","author":"Davis","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb0960","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2174\/1381612825666190708192134","article-title":"Obesity, metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus","volume":"25","author":"Katsiki","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.metabol.2022.155332_bb0965","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2005.04784.x","article-title":"A meta-analysis of the effect of thiazolidinediones on blood pressure","volume":"8","author":"Qayyum","year":"2006","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.metabol.2022.155332_bb0970","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","article-title":"Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis","volume":"55","author":"Sarafidis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.metabol.2022.155332_bb0975","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.dsx.2018.04.013","article-title":"Effect of pioglitazone on decreasing of proteinuria in type 2 diabetic patients with nephropathy","volume":"13","author":"Pourshabanan","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.metabol.2022.155332_bb0980","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabet.2018.10.003","article-title":"Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb0985","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb0990","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb0995","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1000","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.08.010","article-title":"Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials","volume":"68","author":"Zhu","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2022.155332_bb1010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.metabol.2022.155332_bb1015","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1210\/en.2004-0735","article-title":"Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation","volume":"146","author":"Ali","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2022.155332_bb1020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","article-title":"Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive","volume":"32","author":"Dormandy","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.metabol.2022.155332_bb1025","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/dom.12608","article-title":"Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes","volume":"18","author":"Erdmann","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1030","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1035","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archinternmed.2012.1938","article-title":"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes","volume":"172","author":"Idris","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ajo.2008.10.016","article-title":"Glitazone use associated with diabetic macular edema","volume":"147","author":"Fong","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.metabol.2022.155332_bb1045","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ajo.2017.12.007","article-title":"Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD EYE study","volume":"187","author":"Gower","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.metabol.2022.155332_bb1050","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(05)67504-6","article-title":"The PROactive study: some answers, many questions","volume":"366","author":"Yki-J\u00e4rvinen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1055","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1060","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb1065","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ahj.2013.05.004","article-title":"Results of a reevaluation of cardiovascular outcomes in the RECORD trial","volume":"166","author":"Mahaffey","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2022.155332_bb1075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","article-title":"Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial","volume":"128","author":"Bach","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb1080","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/dom.13344","article-title":"Impact of treatment with pioglitazone on stroke outcomes: a real-world database analysis","volume":"20","author":"Morgan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1085","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1007\/s10072-020-04494-3","article-title":"Thiazolidinedione use is associated with reduced risk of Parkinson's disease in patients with diabetes: a meta-analysis of real-world evidence","volume":"41","author":"Hussain","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb1095","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fendo.2018.00613","article-title":"The discovery of insulin: an important milestone in the history of medicine","volume":"9","author":"Vecchio","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154737","article-title":"Diabetes mellitus: 100 years since the discovery of insulin","volume":"118","author":"Polyzos","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154941","article-title":"Insulin discovery: a pivotal point in medical history","volume":"127","author":"Falcetta","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155142","article-title":"Insulin: the master regulator of glucose metabolism","volume":"129","author":"Norton","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154935","article-title":"One-hundred year evolution of prandial insulin preparations: from animal pancreas extracts to rapid-acting analogs","volume":"126","author":"Bolli","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin analogues","volume":"352","author":"Hirsch","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1125","article-title":"The continuum of insulin development viewed in the context of a collaborative process toward leveraging science to save lives: following the trail of publications and patents one century after insulin's first use in humans","volume":"155251","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1130","series-title":"StatPearls","article-title":"Insulin","author":"Thota","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb1135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"Beta-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1140","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.clinthera.2007.07.003","article-title":"Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison","volume":"29","author":"Ilag","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12020-012-9817-6","article-title":"Insulin therapy for type 2 diabetes","volume":"43","author":"Meneghini","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.metabol.2022.155332_bb1150","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1155","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.2337\/diacare.27.11.2597","article-title":"Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function","volume":"27","author":"Li","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.metabol.2022.155332_bb1160","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.2337\/dc09-S318","article-title":"Insulin therapy for type 2 diabetes","volume":"32","author":"Swinnen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1165","first-page":"107","article-title":"Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes","volume":"11","author":"Joseph","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2022.155332_bb1170","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s13300-020-00925-8","article-title":"The safety and efficacy of second-generation basal insulin analogues in adults with type 2 diabetes at risk of hypoglycemia and use in other special populations: a narrative review","volume":"11","author":"Cheng","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1175","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s12325-019-00925-6","article-title":"Differentiating basal insulin preparations: understanding how they work explains why they are different","volume":"36","author":"Cheng","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1180","series-title":"Endotext","article-title":"Insulin \u2013 pharmacology, therapeutic regimens, and principles of intensive insulin therapy","author":"Donner","year":"2000"},{"key":"10.1016\/j.metabol.2022.155332_bb1185","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro","volume":"49","author":"Lepore","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/dmrr.2763","article-title":"The past, present, and future of basal insulins","volume":"32","author":"Pettus","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1195","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1200","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.2337\/dc08-1874","article-title":"Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study","volume":"32","author":"Bolli","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1205","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.23.6.813","article-title":"Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites","volume":"23","author":"Owens","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1210","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb1215","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1220","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006383.pub2","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","author":"Swinnen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1225","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1517\/14712598.2014.970633","article-title":"U300, a novel long-acting insulin formulation","volume":"14","author":"Sutton","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1230","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 units \u00b7 mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units \u00b7 mL-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1240","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc15-0249","article-title":"New insulin glargine 300 Units\/mL versus glargine 100 units\/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4)","volume":"38","author":"Home","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1245","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","article-title":"A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.metabol.2022.155332_bb1250","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/dom.12416","article-title":"Low within- and between-day variability in exposure to new insulin glargine 300 U\/ml","volume":"17","author":"Becker","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1255","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/dc16-0684","article-title":"Comparison of insulin glargine 300 units\/mL and 100 units\/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections","volume":"40","author":"Bergenstal","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12955-018-0883-1","article-title":"When insulin degludec enhances quality of life in patients with type 2 diabetes: a qualitative investigation","volume":"16","author":"Weatherall","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.metabol.2022.155332_bb1265","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000548","article-title":"Improved diabetes medication convenience and satisfaction in persons with type 2 diabetes after switching to insulin glargine 300 U\/mL: results of the observational OPTIN-D study","volume":"6","author":"Wieringa","year":"2018","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1270","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/dom.13105","article-title":"Better glycaemic control and less hypoglycaemia with insulin glargine 300 U\/mL vs glargine 100 U\/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes","volume":"20","author":"Ritzel","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1275","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1280","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1285","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/dom.12485","article-title":"Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes","volume":"17","author":"Ritzel","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1290","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1295","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/dom.14043","article-title":"Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes: a subanalysis from the BRIGHT trial","volume":"22","author":"Haluz\u00edk","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1300","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","article-title":"More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1305","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ahj.2016.06.004","article-title":"Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events) - DEVOTE 1","volume":"179","author":"Marso","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2022.155332_bb1315","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12933-019-0960-8","article-title":"DEVOTE Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14","volume":"18","author":"Pratley","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb1320","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/dmrr.912","article-title":"Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells","volume":"25","author":"Weinstein","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1330","first-page":"S83","article-title":"6. Glycemic targets: standards of medical care in diabetes\u20142022","volume":"45","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1335","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2337\/dc07-2137","article-title":"Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine","volume":"31","author":"Bergenstal","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1340","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2012.01580.x","article-title":"The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences","volume":"14","author":"Home","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1345","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13300-019-00732-w","article-title":"Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes","volume":"11","author":"Nicolucci","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1350","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JXX.0000000000000261","article-title":"Role of ultrafast-acting insulin analogues in the management of diabetes","volume":"31","author":"Kruger","year":"2019","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb1355","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2337\/dc16-1770","article-title":"Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the onset 2 trial","volume":"40","author":"Bowering","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1360","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/dme.13866","article-title":"Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant type 2 diabetes","volume":"36","author":"Bowering","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1365","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.2337\/dc19-2550","article-title":"Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D","volume":"43","author":"Blevins","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1370","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4568903","article-title":"Rethinking the viability and utility of inhaled insulin in clinical practice","volume":"2018","author":"Heinemann","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.metabol.2022.155332_bb1375","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/193229680800200206","article-title":"Inhaled technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes","volume":"2","author":"Rave","year":"2008","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.metabol.2022.155332_bb1380","unstructured":"MannKind CorporationTM. AFREZZA\u00ae (insulin human) Inhalation Powder. AccessdataFDAGov n.d.:35."},{"key":"10.1016\/j.metabol.2022.155332_bb1385","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/S0140-6736(10)60632-0","article-title":"Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial","volume":"375","author":"Rosenstock","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1390","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6536178","article-title":"Efficacy, safety, and quality of treatment satisfaction of premixed human and analogue insulin regimens in a large cohort of type 2 diabetic patients: PROGENS BENEFIT observational study","volume":"2018","author":"Nabrdalik","year":"2018","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1395","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/dc07-1122","article-title":"Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension\/lispro) versus basal\/bolus (glargine\/lispro) therapy","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1400","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1405","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1410","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2337\/diacare.28.2.260","article-title":"Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs","volume":"28","author":"Raskin","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1415","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1464-5491.2005.01511.x","article-title":"Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes","volume":"22","author":"Malone","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1420","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2337\/diaspect.29.3.152","article-title":"Basal insulin use with GLP-1 receptor agonists","volume":"29","author":"Anderson","year":"2016","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.metabol.2022.155332_bb1425","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/dom.14148","article-title":"Insulin glargine\/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and Bayesian network meta-analysis","volume":"22","author":"Home","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1430","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcjd.2020.05.007","article-title":"Case series of U-500 insulin use in adults with type 2 diabetes and severe insulin resistance","volume":"45","author":"Zamora","year":"2021","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1435","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154889","article-title":"Future directions in insulin therapy","volume":"124","author":"Home","year":"2021","journal-title":"Metabolism"},{"issue":"Supp.155051","key":"10.1016\/j.metabol.2022.155332_bb1440","article-title":"Patient perspectives and experiences of basal insulin (BI) titration in type 2 diabetes (T2D): a US cross-sectional survey","volume":"128","author":"Harris","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1445","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/014572179902500310","article-title":"Clinical implications of amylin and amylin deficiency","volume":"25","author":"Kruger","year":"1999","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.metabol.2022.155332_bb1450","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1370\/afm.1174","article-title":"Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus","volume":"8","author":"Lee","year":"2010","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ecl.2004.11.006","article-title":"Novel pharmacologic agents for type 2 diabetes","volume":"34","author":"Uwaifo","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2022.155332_bb1460","author":"<collab>Amylin Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb1465","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/vhrm.2006.2.3.203","article-title":"Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes","volume":"2","author":"Pullman","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2022.155332_bb1470","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1345\/aph.1C387","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb1475","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2147\/VHRM.S1978","article-title":"Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk","volume":"4","author":"Hoogwerf","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2022.155332_bb1480","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc09-0395","article-title":"Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes","volume":"32","author":"Riddle","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1485","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.clinthera.2007.04.005","article-title":"Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus","volume":"29","author":"Singh-Franco","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1490","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1495","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2004","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1500","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1505","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1463-1326.2010.01337.x","article-title":"The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis","volume":"13","author":"Singh-Franco","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1510","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1463-1326.2004.00417.x","article-title":"The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes","volume":"7","author":"Amiel","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1515","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40842-016-0030-z","article-title":"Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials","volume":"2","author":"Herrmann","year":"2016","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1520","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.clinthera.2005.10.009","article-title":"Pramlintide in the treatment of type 1 and type 2 diabetes mellitus","volume":"27","author":"Ryan","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1525","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14302","article-title":"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes","volume":"23","author":"Andersen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1530","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1C and body weight in insulin-treated african americans and hispanics with type 2 diabetes: a pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1535","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1540","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1545","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1555","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154843","article-title":"Incretin-based therapies in 2021 - current status and perspectives for the future","volume":"122","author":"Rizzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1560","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1565","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1570","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb1575","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.metabol.2022.155332_bb1580","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1585","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ph14020144","article-title":"Novel potent and selective DPP-4 inhibitors: design, synthesis and molecular docking study of dihydropyrimidine phthalimide hybrids","volume":"14","author":"Mourad","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb1590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1595","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2213-8587(14)70251-7","article-title":"Once-weekly trelagliptin versus daily alogliptin in japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study","volume":"3","author":"Inagaki","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1600","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/dom.12832","volume":"19","author":"Goldenberg","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1605","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3389\/fendo.2019.00389","article-title":"Clinical use of DPP-4 inhibitors","volume":"10","author":"Gallwitz","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1610","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/1440-1681.12455","article-title":"Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus","volume":"42","author":"Chen","year":"2015","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.metabol.2022.155332_bb1615","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","article-title":"The safety of gliptins: updated data in 2018","volume":"17","author":"Scheen","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.metabol.2022.155332_bb1620","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.2012.04173.x","article-title":"Pharmacokinetics of linagliptin in subjects with hepatic impairment","volume":"74","author":"Graefe-Mody","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb1625","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","article-title":"Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy","volume":"11","author":"Ferrannini","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1630","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2174\/1573399815666190321144310","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta-analysis","volume":"16","author":"Abdelaziz","year":"2020","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1635","series-title":"StatPearls","article-title":"Dipeptidyl peptidase IV (DPP IV) inhibitors","author":"Kasina","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb1640","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clinthera.2006.01.015","article-title":"Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers","volume":"28","author":"Bergman","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1645","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0091270006299137","article-title":"Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT","volume":"47","author":"He","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb1650","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.clinthera.2008.03.005","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects","volume":"30","author":"Christopher","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1655","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","article-title":"Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"14","author":"Goo\u00dfen","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1660","series-title":"Research C for DE and. FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes","year":"2019"},{"key":"10.1016\/j.metabol.2022.155332_bb1665","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2337\/dc15-1707","article-title":"Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes","volume":"40","author":"Tk\u00e1\u010d","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1670","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/s41598-017-19055-6","article-title":"Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis","volume":"8","author":"Pinto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2022.155332_bb1675","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1680","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb1685","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamainternmed.2016.1522","article-title":"Association between incretin-based drugs and the risk of acute pancreatitis","volume":"176","author":"Azoulay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1690","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001906","article-title":"Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study","volume":"94","author":"Lai","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.metabol.2022.155332_bb1695","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107981","article-title":"Pancreatitis and pancreatic cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials","volume":"159","author":"Dicembrini","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb1700","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dsx.2018.08.012","article-title":"Dipeptidyl peptidase-4 inhibitors: anti-diabetic drugs with potential effects on cancer","volume":"13","author":"Almagthali","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.metabol.2022.155332_bb1705","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb1710","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb1715","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2017.05.013","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis","volume":"43","author":"Men","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1720","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/dom.12377","article-title":"Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study","volume":"16","author":"Del Prato","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1725","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb1730","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0091270008316885","article-title":"Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension","volume":"48","author":"Mistry","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb1735","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3389\/fimmu.2019.01050","article-title":"DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2022.155332_bb1740","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: systematic review and meta-analysis","volume":"29","author":"Monami","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1745","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1750","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1755","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1760","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb1765","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00380-020-01711-z","article-title":"DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism","volume":"36","author":"Furukawa","year":"2021","journal-title":"Heart Vessels"},{"key":"10.1016\/j.metabol.2022.155332_bb1770","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"132","author":"Cirica","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb1775","series-title":"Research C for DE and. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin","year":"2019"},{"key":"10.1016\/j.metabol.2022.155332_bb1780","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1785","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"VIVIDD trial committees and investigators. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.metabol.2022.155332_bb1790","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jdi.13078","article-title":"Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke","volume":"11","author":"Chen","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2022.155332_bb1795","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1800","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/1753-0407.12616","article-title":"The kidney and cardiovascular outcome trials","volume":"10","author":"Bloomgarden","year":"2018","journal-title":"J Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1805","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jdi.12142","article-title":"Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus","volume":"5","author":"Mori","year":"2014","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.metabol.2022.155332_bb1810","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.numecd.2016.01.001","article-title":"Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury","volume":"26","author":"Penno","year":"2016","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2022.155332_bb1815","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","article-title":"Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study","volume":"8","author":"Kohsaka","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1825","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1830","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1835","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1840","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb1845","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7\u201336)NH2, GLP-1-(7\u201337), and GLP-1- (9\u201336)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1850","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon-like peptide-1 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb1855","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb1860","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1210\/jc.2014-2291","article-title":"Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study","volume":"100","author":"Rizzo","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1865","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2016.03.002","article-title":"Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation","volume":"95","author":"Fern\u00e1ndez-Mill\u00e1n","year":"2016","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1870","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/591056","article-title":"An emerging role of glucagon-like Peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes","volume":"2013","author":"Puddu","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.metabol.2022.155332_bb1875","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2022.155332_bb1880","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fendo.2018.00719","article-title":"Glucagon like peptide 1 and MicroRNA in metabolic diseases: focusing on GLP1 action on miRNAs","volume":"9","author":"Capuani","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1885","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fphar.2018.01168","article-title":"GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress","volume":"9","author":"Jiang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb1890","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb1895","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb1900","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1905","doi-asserted-by":"crossref","first-page":"734","DOI":"10.2337\/diabetes.52.3.734","article-title":"Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat","volume":"52","author":"Stoffers","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb1910","first-page":"491","article-title":"Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials","volume":"11","author":"Madsbad","year":"2008","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1915","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","article-title":"Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists","volume":"6","author":"Uccellatore","year":"2015","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb1920","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1463-1326.2012.01560.x","article-title":"GLP-1 based therapies: differential effects on fasting and postprandial glucose","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1925","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-5491.2006.01800.x","article-title":"Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes","volume":"23","author":"Linnebjerg","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1930","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1935","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1940","article-title":"Standards of medical care in diabetes-2017: summary of revisions","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1945","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb1950","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","article-title":"Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial","volume":"375","author":"Diamant","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1955","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb1960","unstructured":"Amylin Pharmaceuticals, Inc. Byetta (exenatide) injection. AccessdataFDAGov n.d.:34."},{"key":"10.1016\/j.metabol.2022.155332_bb1965","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. Placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2022.155332_bb1970","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dom.12121","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)","volume":"15","author":"Pinget","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb1980","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agers\u00f8","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb1985","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2021.154997","article-title":"Liraglutide in treatment of diabetes mellitus type 2: systematic review and bibliometric analysis over the last two decades","volume":"128","author":"Kamal","year":"2022","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2022.155332_bb1990","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2000","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation [published correction appears in Endocrinology. 2012 Feb;153(2):1000. Moerch, Ulrik [Added]]","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2022.155332_bb2005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.metabol.2022.155332_bb2015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial [published correction appears in Lancet Diabetes Endocrinol","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2020","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2030","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2035","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10192","key":"10.1016\/j.metabol.2022.155332_bb2040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial [published correction appears in lancet","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2045","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMc1913157","article-title":"Oral semaglutide and cardiovascular outcomes in type 2 diabetes","volume":"381","author":"Zweck","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2050","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","article-title":"Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes","volume":"58","author":"Granhall","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2022.155332_bb2055","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2022.155332_bb2065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2070","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes [published online ahead of print","volume":"10","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2075","series-title":"Efficacy and safety of LY3298176 once weekly versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk (SURPASS-4)","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb2080","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2085","series-title":"The effect of tirzepatide versus dulaglutide on major adverse cardiovascular events in patients with type 2 diabetes (SURPASS-CVOT)","year":"2022"},{"key":"10.1016\/j.metabol.2022.155332_bb2090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/dmrr.499","article-title":"Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes","volume":"20","author":"Fineman","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"10.1016\/j.metabol.2022.155332_bb2095","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs\u2013FDA and EMA assessment [published correction appears in N","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2105","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2110","first-page":"874","article-title":"Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial [published correction appears in Arch Ophthalmol 1998 Nov; 116(11):1469","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.metabol.2022.155332_bb2115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label,randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2135","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2140","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized,controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2145","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1185\/03007995.2016.1168291","article-title":"Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus","volume":"32","author":"Iglay","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.metabol.2022.155332_bb2150","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2155","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2012.11.009","article-title":"Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type 2 diabetes","volume":"100","author":"Herzlinger","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2022.155332_bb2170","first-page":"13","article-title":"Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study","author":"Rizzo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb2175","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2180","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2185","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2190","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2200","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2205","series-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","author":"Gerstein","year":"2021"},{"key":"10.1016\/j.metabol.2022.155332_bb2210","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2022.155332_bb2215","first-page":"687","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical","volume":"314","author":"Davies","year":"2015","journal-title":"Trial"},{"key":"10.1016\/j.metabol.2022.155332_bb2220","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2230","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2235","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2240","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2245","first-page":"1002","article-title":"The GLP-1 receptor agonist semaglutide for the treatment of nonalcoholic steatohepatitis","author":"Dichtel","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2022.155332_bb2255","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabetes Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SLGT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.metabol.2022.155332_bb2265","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2270","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2275","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb2280","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/00365517109090668","article-title":"Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects","volume":"28","author":"Mogensen","year":"1971","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.metabol.2022.155332_bb2285","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","article-title":"The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia","volume":"14","author":"DeFronzo","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2290","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2295","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb2300","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1042\/CS20171374","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular events in patients with diabetes: information from clinical trials and observational real-world data","volume":"132","author":"Ferrannini","year":"2018","journal-title":"Clin Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb2305","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose contransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2310","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.2174\/1381612823666170113152742","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management","volume":"23","author":"Katsiki","year":"2017","journal-title":"Curr Pharm Des"},{"issue":"124 Suppl 1","key":"10.1016\/j.metabol.2022.155332_bb2315","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.amjcard.2019.10.028","article-title":"Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits","volume":"15","author":"Verma","year":"2019","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.metabol.2022.155332_bb2320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4239\/wjd.v11.i7.269","article-title":"Sodium-glucose cotransporter 2 inhibitors' mechanisms of action in heart failure","volume":"15;11","author":"Grubi\u0107 Rotkvi\u0107","year":"2020","journal-title":"World J Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb2325","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154799","article-title":"Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"120","author":"Prattichizzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2330","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154936","article-title":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","volume":"127","author":"Marfella","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2335","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2019.154045","article-title":"Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure","volume":"104","author":"Giorgino","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2340","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2345","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155243","article-title":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","author":"Sardu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2355","unstructured":"N Katsiki G Dimitriadis D Mikhailidis. Serum uric acid and diabetes: from pathophysiology to cardiovascular disease n.d."},{"key":"10.1016\/j.metabol.2022.155332_bb2360","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","article-title":"Serum uric acid and the risk of cardiovascular and renal disease","volume":"33","author":"Borghi","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2022.155332_bb2365","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2370","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"372","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2375","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2380","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1161\/01.CIR.102.25.3032","article-title":"Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) investigators","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2385","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb2390","series-title":"EMPA-HEART CardioLink-6 trial: A randomized trial of empagliflozin on left ventricular structure, function, and biomarkers in people with type 2 diabetes and coronary heart disease","author":"Verma","year":"2018"},{"key":"10.1016\/j.metabol.2022.155332_bb2395","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb2400","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14779072.2020.1822069","article-title":"Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention","volume":"18","author":"Katsiki","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb2405","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: A. Systematic review and meta-analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.metabol.2022.155332_bb2410","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb2415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb2420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb2425","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.metabol.2022.155332_bb2430","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2337\/db11-1805","article-title":"Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans","volume":"61","author":"Labbe","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb2435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107723","article-title":"Anti-inflammatory properties of antidiabetic drugs: a \u201cpromised land\u201d in the COVID-19 era?","volume":"34","author":"Katsiki","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2022.155332_bb2440","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.metabol.2022.155332_bb2445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12933-018-0745-5","article-title":"Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors","volume":"17","author":"Lahnwong","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb2450","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2455","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2460","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2465","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-016-0440-3","article-title":"Glucagon and heart in type 2 diabetes: new perspectives","volume":"15","author":"Cerielllo","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2022.155332_bb2470","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2475","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: ex quo et quo vadimus?","volume":"98","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2480","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb2485","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jdiacomp.2016.12.006","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs","volume":"31","author":"Katsiki","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2022.155332_bb2490","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb2495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hjc.2020.02.009","article-title":"Diabetes mellitus and comorbidities: a bad romance","volume":"61","author":"Katsiki","year":"2020","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2500","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2505","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14656566.2017.1351946","article-title":"Cardiovascular disease prevention strategies for type 2 diabetes mellitus","volume":"18","author":"Katsiki","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2022.155332_bb2510","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154333","article-title":"Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)\/DASH (dysmetabolism associated steatohepatitis)","volume":"114","author":"Katsiki","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2515","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2520","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2525","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2022.155332_bb2530","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161115666170621075619","article-title":"Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb2535","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk.An expert panel statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2540","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2545","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2550","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and safety CardioVascular outcomes trial (VERTIS-CV)","volume":"206","author":"Cannon","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2022.155332_bb2555","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2560","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomized, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2565","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2570","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2575","author":"<collab>Janssen Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb2580","author":"<collab>Boehringer Ingelheim Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb2590","author":"Co."},{"key":"10.1016\/j.metabol.2022.155332_bb2595","series-title":"FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)","year":"2016"},{"key":"10.1016\/j.metabol.2022.155332_bb2600","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2605","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2610","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide registerbased cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb2615","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2620","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1056\/NEJMc1701990","article-title":"Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor","volume":"376","author":"Fralick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2625","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2630","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2635","doi-asserted-by":"crossref","first-page":"594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium-glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open"},{"key":"10.1016\/j.metabol.2022.155332_bb2640","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.metabol.2022.155332_bb2645","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence","volume":"96","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2650","series-title":"FDA removes Boxed Warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)","year":"2020"},{"key":"10.1016\/j.metabol.2022.155332_bb2655","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb2660","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2665","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1161\/CIRCULATIONAHA.118.038339","article-title":"Empagliflozin is associated with a lower risk of post-acute heart failure rehospitalization and mortality","volume":"139","author":"Savarese","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2670","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes and prior myocardial infarction: a sub-analysis from DECLARE TIMI-58 trial","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2675","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2680","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2685","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT2-inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2690","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2695","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.metabol.2022.155332_bb2700","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.metabol.2022.155332_bb2705","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2710","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2715","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2720","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","article-title":"Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction","volume":"80","author":"Cunningham","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2725","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomized, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2730","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2735","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.metabol.2022.155332_bb2740","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2745","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomized trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb2750","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875","article-title":"Empagliflozin improves kidney outcomes in patients with or without heart failure","volume":"12","author":"Butler","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.metabol.2022.155332_bb2755","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes in patients with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2022.155332_bb2760","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose contransporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.metabol.2022.155332_bb2765","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.metabol.2022.155332_bb2770","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2775","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2780","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2785","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2790","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTANA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2022.155332_bb2795","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2800","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb2805","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.metabol.2022.155332_bb2815","first-page":"S76","article-title":"GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity","volume":"153","author":"Overton","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb2820","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.drudis.2013.09.011","article-title":"GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119","volume":"18","author":"Kang","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.metabol.2022.155332_bb2825","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1021\/acs.jmedchem.5b01198","article-title":"G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: recent progress and prevailing challenges","volume":"59","author":"Ritter","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2022.155332_bb2830","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-beta (TR\u03b2) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2835","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2147\/DMSO.S330515","article-title":"TRC150094, a novel mitochondrial modulator, reduces cardio-metabolic risk as an add-on treatment: a phase-2, 24-week, multi-center, randomized, double-blind,clinical trial","volume":"15","author":"Joshi","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2022.155332_bb2840","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2019.104373","article-title":"Anti-diabetic compounds from the seeds of Psoralea corylifolia","volume":"139","author":"Zhu","year":"2019","journal-title":"Fitoterapia"},{"key":"10.1016\/j.metabol.2022.155332_bb2845","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/ph13080199","article-title":"A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors","volume":"13","author":"Lau","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb2850","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103981","article-title":"Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus","volume":"9","author":"Kolodka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2022.155332_bb2855","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lfs.2018.09.009","article-title":"Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt\/\u03b2-catenin pathway","volume":"210","author":"Zhao","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb2860","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2022.155332_bb2865","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/dom.14009","article-title":"The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized, placebo-controlled trial","volume":"22","author":"Wentworth","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2870","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/CRD.0000000000000258","article-title":"Angiopoietin-like 3 protein inhibition: a new frontier in lipid-lowering treatment","volume":"27","author":"Lang","year":"2019","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb2875","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154921","article-title":"Angiopoietin-like protein 8 (betatrophin) inhibits hepatic gluconeogenesis through PI3K\/Akt signaling pathway in diabetic mice","volume":"126","author":"Zhao","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb2880","doi-asserted-by":"crossref","first-page":"6578327","DOI":"10.1155\/2019\/6578327","article-title":"Effects of angiopoietin-like 3 on triglyceride regulation, glucose homeostasis, and diabetes","volume":"2019","author":"Christopoulou","year":"2019","journal-title":"Dis Markers"},{"key":"10.1016\/j.metabol.2022.155332_bb2885","first-page":"241","article-title":"AMPK activation: a therapeutic target for type 2 diabetes?","volume":"7","author":"Coughlan","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.metabol.2022.155332_bb2890","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41573-019-0019-2","article-title":"AMP-activated protein kinase: the current landscape for drug development","volume":"18","author":"Steinberg","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2022.155332_bb2895","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fphys.2019.00148","article-title":"The central role of glucokinase in glucose homeostasis: a perspective 50 years after demonstrating the presence of the enzyme in islets of Langerhans","volume":"10","author":"Matschinsky","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.metabol.2022.155332_bb2900","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40265-020-01278-z","article-title":"Glucokinase activators for type 2 diabetes: challenges and future developments","volume":"80","author":"Toulis","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2022.155332_bb2905","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/682673","article-title":"Fructose: a key factor in the development of metabolic syndrome and hypertension","volume":"2013","author":"Khitan","year":"2013","journal-title":"J Nutr Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb2910","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107555","article-title":"A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus","volume":"34","author":"Lee","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2022.155332_bb2915","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/ph14111196","article-title":"MLR-1023 treatment in mice and humans induces a thermogenic program, and menthol potentiates the effect","volume":"14","author":"Rebello","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.metabol.2022.155332_bb2920","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/ars.2009.2531","article-title":"Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities","volume":"12","author":"Sivitz","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.metabol.2022.155332_bb2925","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.febslet.2008.11.041","article-title":"Structural analysis of human glutamine:fructose-6-phosphate amidotransferase, a key regulator in type 2 diabetes","volume":"583","author":"Nakaishi","year":"2009","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2022.155332_bb2930","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cell.2017.06.011","article-title":"Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms","volume":"170","author":"Rusu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2022.155332_bb2935","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2022.155332_bb2940","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2017.06.024","article-title":"A new drug target for type 2 diabetes","volume":"170","author":"Stadler","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2022.155332_bb2945","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12079-010-0095-x","article-title":"A novel role of CCN3 in regulating endothelial inflammation","volume":"4","author":"Lin","year":"2010","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.metabol.2022.155332_bb2950","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.2337\/db15-0617","article-title":"NOV\/CCN3: a new adipocytokine involved in obesity-associated insulin resistance","volume":"65","author":"Martinerie","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb2955","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cca.2019.03.006","article-title":"Serum CCN3 levels are increased in type 2 diabetes mellitus and associated with obesity, insulin resistance and inflammation","volume":"494","author":"Li","year":"2019","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.metabol.2022.155332_bb2960","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173758","article-title":"FoxO1 signaling as a therapeutic target for type 2 diabetes and obesity","volume":"891","author":"Benchoula","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb2965","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tcb.2016.01.002","article-title":"Nuclear mechanisms of insulin resistance","volume":"26","author":"Kang","year":"2016","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.metabol.2022.155332_bb2970","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.M301403200","article-title":"Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation","volume":"278","author":"Le Poul","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2022.155332_bb2975","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fphar.2014.00236","article-title":"Free fatty acid receptors as therapeutic targets for the treatment of diabetes","volume":"5","author":"Ichimura","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.metabol.2022.155332_bb2980","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.tips.2016.08.001","article-title":"Epoxyeicosatrienoic acid as therapy for diabetic and ischemic cardiomyopathy","volume":"37","author":"Romashko","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb2985","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1089\/scd.2016.0072","article-title":"Epoxyeicosatrienoic acids regulate adipocyte differentiation of mouse 3T3 cells, via PGC-1\u03b1 activation, which is required for HO-1 expression and increased mitochondrial function","volume":"25","author":"Waldman","year":"2016","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.metabol.2022.155332_bb2990","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1073\/pnas.061035098","article-title":"Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1","volume":"98","author":"Michael","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.metabol.2022.155332_bb2995","doi-asserted-by":"crossref","first-page":"36642","DOI":"10.1074\/jbc.M707006200","article-title":"A role for the transcriptional coactivator PGC-1alpha in muscle refueling","volume":"282","author":"Wende","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2022.155332_bb3000","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1534-5807(03)00274-0","article-title":"Genetic modulation of PPAR gamma phosphorylation regulates insulin sensitivity","volume":"5","author":"Rangwala","year":"2003","journal-title":"Dev Cell"},{"key":"10.1016\/j.metabol.2022.155332_bb3005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2022.155332_bb3010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1517\/14728222.11.11.1503","article-title":"Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat type 2 diabetes","volume":"11","author":"Pascual","year":"2007","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.metabol.2022.155332_bb3015","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1210\/me.2014-1062","article-title":"Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues","volume":"28","author":"Patel","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb3020","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1210\/me.2003-0283","article-title":"Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus","volume":"18","author":"Opherk","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb3025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.tcb.2016.01.002","article-title":"Nuclear mechanisms of insulin resistance","volume":"26","author":"Kang","year":"2016","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.metabol.2022.155332_bb3030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.abb.2014.12.012","article-title":"The Keap1-Nrf2 system and diabetes mellitus","volume":"566","author":"Uruno","year":"2015","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.metabol.2022.155332_bb3035","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2337\/db09-1342","article-title":"The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy","volume":"59","author":"Jiang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb3040","doi-asserted-by":"crossref","first-page":"20290","DOI":"10.3390\/ijms151120290","article-title":"Nrf2 and redox status in prediabetic and diabetic patients","volume":"15","author":"Jim\u00e9nez-Osorio","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2022.155332_bb3045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/pr.117.014753","article-title":"Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach","volume":"70","author":"Cuadrado","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb3050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0167-0115(95)00063-H","article-title":"Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7\u201336) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides","volume":"58","author":"Hupe-Sodmann","year":"1995","journal-title":"Regul Pept"},{"key":"10.1016\/j.metabol.2022.155332_bb3055","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2022.155332_bb3060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/19382014.2018.1502521","article-title":"Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner","volume":"10","author":"Esser","year":"2018","journal-title":"Islets"},{"key":"10.1016\/j.metabol.2022.155332_bb3065","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2022.155332_bb3070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"issue":"7258","key":"10.1016\/j.metabol.2022.155332_bb3075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb3080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jdiacomp.2011.10.003","article-title":"The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA diabetes trial","volume":"25","author":"Duckworth","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"24","key":"10.1016\/j.metabol.2022.155332_bb3085","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.metabol.2022.155332_bb3090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/cd17-0083","article-title":"Personalizing type 2 diabetes management: use of a patient-centered approach to individualizing A1C goals and pharmacological regimens","volume":"35","author":"Lahiri","year":"2017","journal-title":"Clin Diabetes"},{"issue":"3","key":"10.1016\/j.metabol.2022.155332_bb3095","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3109","article-title":"Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine","volume":"35","author":"Mannino","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb3100","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.1999.17.10.3291","article-title":"Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults","volume":"17","author":"Kaklamani","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.metabol.2022.155332_bb3105","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.2337\/dc07-1257","article-title":"Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training","volume":"30","author":"Bl\u00fcher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb3110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3945\/ajcn.2008.26480","article-title":"Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study","volume":"88","author":"Fargnoli","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2022.155332_bb3115","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/db10-1791","article-title":"Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance","volume":"60","author":"Moon","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2022.155332_bb3120","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/dc06-0221","article-title":"Dietary fibers and glycemic load, obesity, and plasma adiponectin levels in women with type 2 diabetes","volume":"29","author":"Qi","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb3125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/dmrr.1092","article-title":"The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach","volume":"26","author":"Pozzilli","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.metabol.2022.155332_bb3130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12020-013-0128-3","article-title":"SMART diabetes: the way to go (safe and multifactorial approach to reduce the risk for therapy in diabetes)","volume":"46","author":"Maddaloni","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.metabol.2022.155332_bb3135","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.317.7167.1202","article-title":"Randomised controlled trial of patient centred care of diabetes in general practice: impact on current wellbeing and future disease risk. The Diabetes Care from Diagnosis Research Team","volume":"317","author":"Kinmonth","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2022.155332_bb3140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.metabol.2018.10.010","article-title":"Pharmacotherapy of obesity: available medications and drugs under investigation","volume":"92","author":"Pilitsi","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb3145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.metabol.2022.155332_bb3150","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2022.155332_bb3155","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2022.155332_bb3160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2042018818763698","article-title":"The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes","volume":"9","author":"Inman","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.metabol.2022.155332_bb3165","article-title":"The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: a Bayesian network meta-analysis","volume":"13","author":"Chen","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metabol.2022.155332_bb3170","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154769","article-title":"COVID-19 editorial: mechanistic links and therapeutic challenges for metabolic diseases one year into the COVID-19 pandemic","volume":"119","author":"Tessier","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2022.155332_bb3175","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOL.0000000000000431","article-title":"Adiponectin, lipids and atherosclerosis","volume":"28","author":"Katsiki","year":"2017","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2022.155332_bb3180","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/jcem.83.9.5143","article-title":"Clinical review 97: syndromes of severe insulin resistance","volume":"83","author":"Tritos","year":"1998","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049522002104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:31:31Z","timestamp":1758429091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049522002104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":618,"alternative-id":["S0026049522002104"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155332","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy of type 2 diabetes: An update and future directions","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2022.155332","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155332"}}